Annual CFF
$1.12 M
-$192.61 M-99.42%
December 31, 2023
Summary
- As of February 8, 2025, KPTI annual cash flow from financing activities is $1.12 million, with the most recent change of -$192.61 million (-99.42%) on December 31, 2023.
- During the last 3 years, KPTI annual CFF has fallen by -$170.96 million (-99.35%).
- KPTI annual CFF is now -99.64% below its all-time high of $316.11 million, reached on December 31, 2018.
Performance
KPTI Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
-$40.97 M-100.00%
September 30, 2024
Summary
- As of February 8, 2025, KPTI quarterly cash flow from financing activities is $0.00, with the most recent change of -$40.97 million (-100.00%) on September 30, 2024.
- Over the past year, KPTI quarterly CFF has dropped by -$40.97 million (-100.00%).
- KPTI quarterly CFF is now -100.00% below its all-time high of $167.78 million, reached on December 31, 2018.
Performance
KPTI Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$41.23 M
$0.000.00%
September 30, 2024
Summary
- As of February 8, 2025, KPTI TTM cash flow from financing activities is $41.23 million, unchanged on September 30, 2024.
- Over the past year, KPTI TTM CFF has stayed the same.
- KPTI TTM CFF is now -86.96% below its all-time high of $316.11 million, reached on December 31, 2018.
Performance
KPTI TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
KPTI Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -99.4% | -100.0% | 0.0% |
| 3 y3 years | -99.3% | -100.0% | -46.3% |
| 5 y5 years | -99.6% | -100.0% | -66.8% |
KPTI Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -99.4% | at low | -100.0% | at low | -78.7% | +3568.2% |
| 5 y | 5-year | -99.4% | at low | -100.0% | at low | -85.8% | +3568.2% |
| alltime | all time | -99.6% | at low | -100.0% | +100.0% | -87.0% | +3568.2% |
Karyopharm Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(-100.0%) | $41.23 M(0.0%) |
| Jun 2024 | - | $40.97 M(>+9900.0%) | $41.23 M(+3568.1%) |
| Dec 2023 | $1.12 M(-99.4%) | $264.00 K(>+9900.0%) | $1.12 M(-99.3%) |
| Sep 2023 | - | $0.00(-100.0%) | $156.70 M(-3.6%) |
| Jun 2023 | - | $860.00 K(-99.4%) | $162.50 M(-16.1%) |
| Dec 2022 | $193.74 M(+163.1%) | $155.84 M(+2587.4%) | $193.74 M(+399.4%) |
| Sep 2022 | - | $5.80 M(+341.7%) | $38.79 M(+17.5%) |
| Jun 2022 | - | $1.31 M(-95.7%) | $33.01 M(-64.8%) |
| Mar 2022 | - | $30.78 M(+3335.6%) | $93.75 M(+27.3%) |
| Dec 2021 | $73.65 M(-57.2%) | $896.00 K(+5500.0%) | $73.65 M(-4.0%) |
| Sep 2021 | - | $16.00 K(-100.0%) | $76.72 M(-1.6%) |
| Jun 2021 | - | $62.06 M(+481.3%) | $77.94 M(+334.7%) |
| Mar 2021 | - | $10.68 M(+169.1%) | $17.93 M(-89.6%) |
| Dec 2020 | $172.08 M(+38.4%) | $3.97 M(+220.0%) | $172.08 M(-15.3%) |
| Sep 2020 | - | $1.24 M(-39.4%) | $203.05 M(-30.1%) |
| Jun 2020 | - | $2.05 M(-98.8%) | $290.63 M(+0.6%) |
| Mar 2020 | - | $164.83 M(+371.8%) | $288.98 M(+132.5%) |
| Dec 2019 | $124.31 M(-60.7%) | $34.94 M(-60.7%) | $124.31 M(-51.7%) |
| Sep 2019 | - | $88.82 M(>+9900.0%) | $257.14 M(+52.1%) |
| Jun 2019 | - | $395.00 K(+159.9%) | $169.09 M(-46.5%) |
| Mar 2019 | - | $152.00 K(-99.9%) | $315.83 M(-0.1%) |
| Dec 2018 | $316.11 M | $167.78 M(>+9900.0%) | $316.11 M(+84.5%) |
| Sep 2018 | - | $772.00 K(-99.5%) | $171.29 M(+0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | $147.13 M(>+9900.0%) | $170.68 M(+124.2%) |
| Mar 2018 | - | $429.00 K(-98.1%) | $76.11 M(+0.5%) |
| Dec 2017 | $75.74 M(+48.0%) | $22.96 M(>+9900.0%) | $75.74 M(+5.1%) |
| Sep 2017 | - | $160.00 K(-99.7%) | $72.03 M(-30.3%) |
| Jun 2017 | - | $52.57 M(>+9900.0%) | $103.35 M(+102.6%) |
| Mar 2017 | - | $57.00 K(-99.7%) | $51.02 M(-0.3%) |
| Dec 2016 | $51.16 M(-44.8%) | $19.25 M(-38.9%) | $51.16 M(+53.2%) |
| Sep 2016 | - | $31.48 M(>+9900.0%) | $33.40 M(+1604.9%) |
| Jun 2016 | - | $240.00 K(+22.4%) | $1.96 M(+12.8%) |
| Mar 2016 | - | $196.00 K(-86.8%) | $1.74 M(-98.1%) |
| Dec 2015 | $92.70 M(-18.1%) | $1.48 M(+3705.1%) | $92.70 M(+1.5%) |
| Sep 2015 | - | $39.00 K(+129.4%) | $91.36 M(-55.4%) |
| Jun 2015 | - | $17.00 K(-100.0%) | $204.66 M(+0.2%) |
| Mar 2015 | - | $91.16 M(>+9900.0%) | $204.27 M(+80.6%) |
| Dec 2014 | $113.12 M(-39.2%) | $149.00 K(-99.9%) | $113.12 M(-50.0%) |
| Sep 2014 | - | $113.34 M(<-9900.0%) | $226.13 M(+44.1%) |
| Jun 2014 | - | -$380.00 K(-3023.1%) | $156.97 M(-13.0%) |
| Mar 2014 | - | $13.00 K(-100.0%) | $180.41 M(-3.0%) |
| Dec 2013 | $185.93 M(+1855.3%) | $113.16 M(+156.1%) | $185.93 M(+155.5%) |
| Sep 2013 | - | $44.19 M(+91.6%) | $72.77 M(+154.6%) |
| Jun 2013 | - | $23.06 M(+317.0%) | $28.59 M(+417.0%) |
| Mar 2013 | - | $5.53 M | $5.53 M |
| Dec 2012 | $9.51 M(-20.7%) | - | - |
| Dec 2011 | $11.99 M | - | - |
FAQ
- What is Karyopharm Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics annual CFF year-on-year change?
- What is Karyopharm Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics quarterly CFF year-on-year change?
- What is Karyopharm Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics TTM CFF year-on-year change?
What is Karyopharm Therapeutics annual cash flow from financing activities?
The current annual CFF of KPTI is $1.12 M
What is the all time high annual CFF for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high annual cash flow from financing activities is $316.11 M
What is Karyopharm Therapeutics annual CFF year-on-year change?
Over the past year, KPTI annual cash flow from financing activities has changed by -$192.61 M (-99.42%)
What is Karyopharm Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of KPTI is $0.00
What is the all time high quarterly CFF for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high quarterly cash flow from financing activities is $167.78 M
What is Karyopharm Therapeutics quarterly CFF year-on-year change?
Over the past year, KPTI quarterly cash flow from financing activities has changed by -$40.97 M (-100.00%)
What is Karyopharm Therapeutics TTM cash flow from financing activities?
The current TTM CFF of KPTI is $41.23 M
What is the all time high TTM CFF for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high TTM cash flow from financing activities is $316.11 M
What is Karyopharm Therapeutics TTM CFF year-on-year change?
Over the past year, KPTI TTM cash flow from financing activities has changed by $0.00 (0.00%)